

Quality by Design: Pharmaceutical Development

NAME:

- 1) Gayatri Vijaysing Rajput
- 2) Aishwarya Ganesh Pardeshi
- 3) Bhagyashree Bapu Pawar

Guide Name: Mr. Saeed Ahmed

ABSTRACT

The vital role of quality application via the use of pharmaceutical regulatory papers has been highlighted lately. utilizing quality by design (QbD) concepts to gain a thorough understanding of the process and build product quality in by design design. This paper aims to examine pharmaceutical Quality by Design (QbD) and explain how it may be employed to guarantee the quality of pharmaceuticals. Quality cannot be tested into a product, but it must be built into it. should be constructed by design. It is imperative to define this notion of QbD throughout the design and development of a product. profile of desired product performance [Target Product Profile (TPP), Target Product Quality Profile (TPQP)] and determine the key qualities that contribute to quality (CQA). We may create the product formulation using this. and the method for achieving the product characteristics. These allow us to see the effect of raw materials. [Critical Material Attributes (CMA), Critical Process Parameter (CPP), identification on the CQA's] and the origin of variation. The application of the idea of quality by design (QbD) that is discussed in this book The paper adheres to the concepts outlined in the ICH Q8, Q9, and Q10 guidelines.

Key words: Quality by Design (QbD), Quality target product profile (QTPP), Critical process parameter (CPP), critical quality attribute (CQA), Target product profile (TPP), and Critical material attributes (CMA).

❖ INTRODUCTION

Quality by Design (QbD) includes the design and development of formulations and manufacturing. processes that guarantee certain product criteria. The idea of quality by design (QbD) has Through numerous measures recently embraced by the pharmaceutical sector, such as ICH Q81, Q92, and Process Analytical Technology (PAT)5, the new regulatory documents, and the FDA's cGMP for Q103. 21st Century4. The overall objective is to move away from the quality by testing (QbT) paradigm that was previously used. implemented in the pharmaceutical business with the goal of increasing knowledge of the procedures and the goods, thereby raising the standard of the output, the process's efficiency, and compliance with regulations flexibility.

The knowledge proving the kind of product should be detailed in the Pharmaceutical Development section. The suggested formula and chosen dose form are appropriate for the intended use. This part ought to Make sure that each section contains enough details to help explain the drug's development. [2]The item and its production process.

The guideline that "quality cannot be tested" is included in the policy into products, i.e., quality should be built in by design" In accordance with ICH Q8, QbD is defined as a methodical approach to developing products that takes into account the patient's requirements. A development strategy that starts with predetermined focuses on product and process as well as goals knowledge and process control based on sound principles quality and risk management in science [1].

▪ DEFINITION:

The Quality by Design (QbD) methodology was described as one that includes a greater scientific understanding of the essential process, and product attributes, creating controls and tests during development based on the scientific limits of understanding phase, and applying the information learned throughout the product's life cycle to continually improve it. environment. [3] Everything you do to enhance the safety, efficacy, and quality of your product, from proof of concept to, is covered under the umbrella of Quality by Design. the moment at which customers are purchasing it on a regular basis.

The goal of pharmaceutical development is to create a high-quality product and its production process in order to always provide the product's intended performance. The data and knowledge gained from experience in pharmaceutical development research and production offer a scientific explanation for Promote the development of the design space, specifications, and production controls. Data Quality risk management can be based on pharmaceutical development studies. It's vital to understand that product quality cannot be tested in; rather, it must be designed in. Changes in the processes of formulation and manufacturing throughout development and lifecycle management must be Considered as chances to increase one's understanding and help establish the room for design. The inclusion of pertinent knowledge acquired from experiments that produce unexpected results is another example. The outcomes can also be helpful.

the information proving that the kind of pharmaceutical development is safe and effective should be discussed in the Pharmaceutical Development section. The suggested formulation and chosen dose form are appropriate for the intended use. This chapter ought to Make sure that each component has enough data to explain how the medication evolved the product and its method of production.[2]




Fig No. 1. Content by QbD

QbD refers to improving the planning cycle's effectiveness and lowering expenditures across different phases of development. First, it captures the fundamental quality characteristics and interaction limits that determine the item's character. [4]

▪ Pharmaceutical Quality by Design:

Design-Based Pharmaceutical Quality Quality is defined in ICH Q8 as "The suitability of either a drug substance or drug product for its intended use." The identity, potency, and purity are a few of the qualities covered by this word. The "ICH Q8 guideline" states that: Quality by Design is an organized development methodology that starts with predetermined goals and based on solid science and quality, places emphasis on product and process comprehension and process control risk management.[2]

Pharmaceutical Quality = f (Drug substance,
excipients, manufacturing, and packaging)

ICH Guidelines Q8 for Pharmaceutical Development, Q9 for Quality Risk Management, and Q10 for Quality The basis of QbD is its systems. "Simply testing the product is not enough to guarantee that the procedure consistently yields a product with the desired characteristics. Predetermined criteria. sufficient process planning; understanding and management of variables that lead to Product testing, effective validation experiments, and process variability are all provided together. guarantee that the procedure will result in a product with the necessary quality attributes." [5]

▪ OUTLINE OF QBD: A CHALLENGE TO THE PHARMACEUTICAL INDUSTRY:

QBD-based direction archive for pharmaceutical production that prioritizes item quality and execution and ensured by the plan of viable and well-coordinated assembly processes. The decision of whether an item is an item depends on an intuitive grasp of how definition and improvement elements affect how well an item performs. The producers have the power to sway consistent "genuine time" and continuous advancement. declaration of value. Administrative methods and plans are modified to assess the amount of logical data backing product applications, process authorization, and cycle capability. The extent to which one can rationally understand how detailing and assembly improvements are made is comparable to the degree of risk-based recommendations. The quality of the product, its implementation, and the ability of interaction control systems to prevent the danger of producing a low-quality product are all factors that may be influenced. excellent product.

The real implementation of QbD may result in three main benefits for improvement: • Improved use of resources and time for improvement The ability to adhere to FDA accommodation standards and assumptions Fewer FDA queries and reduced approval times.

The steps involved in creating QBD products:

- Improvement of a new molecular entity: pre-clinical review, non-clinical study, clinical study, scale-up, etc.
- Endorsement and Submission for the Market.
- Making or producing: Real-time quality control, process analytical technology, and configuration space.
- Risk-based selection, Continuous Improvement, and Product Execution are the key components of the Control Strategy [6]

QBD ACROSS THE PRODUCT LIFESPAN:

The planning and design of definitions and manufacturing processes that ensure quality are included in Quality by Design (QbD). Predefined item decisions, Improvement, Preclinical, Nonclinical, and Clinical, Increase Submissions for Market process analytical technology (PAT), endorsement, creating configuration space, "ongoing" quality control, control Planning, making risk-based decisions, continuing improvement, and executing tasks are the six strategies. [10]

QBD DEVELOPMENT PROCESS INCLUDES:

The objective item profile, which reflects the item's use, health, and viability, is where it all begins.

- Describe a quantitative objective product quality profile that will be used by process engineers and formulators. replace components of clinical well-being and viability throughout the process of product improvement.

- Collect relevant prior knowledge about the drug material, possible excipients, and process activities into the area of knowledge. Use risk assessment to concentrate.
- Identify the fundamental interaction boundaries and the information (natural material) credits that should be included in absolute mandates. controlled to achieve these fundamental material credits for the eventual result. Concentrate on the procedure by using risk assessment. material credits and boundaries for the trial check. To plan a space, combine prior knowledge with research. or else a different depiction of the cycle understanding it.
- Establish a control strategy for the entire interaction that may include process, informational material, and other controls. arrange spaces around individual or multiple unit operations, or possibly lead to experiments, using controls and displays. The command The methodology should account for projected variations in scale and be guided by a risk analysis.
- Monitor and update the interaction continuously to ensure consistently high quality.[7]




Fig. No .2. Quality By Design Model

Regulatory bodies often propose ICH quality guidelines for Q8 through Q11. Drug QbD over the long run has evolved with the publication of ICH Q8 (R2) (Drug Development), ICH Q9 (Quality Risk Management), and ICH Q10 (Drug Quality System). The ICH Q8 guideline mentioned the idea of QbD: Which statement demonstrates that "quality can't be"? tried into products, i.e., quality should be planned for. An important element of QbD is understanding how The item characteristics are impacted by interaction and the definition of boundaries, and the consequent enhancement of these boundaries should In the production process, make sure that these boundaries are clearly identified online.[8]

ADVANTAGES OF QBD-

- Get rid of a lot of disappointments.
- Reduce deviations and excessively expensive investigations.
- Avoid administrative consistency problems.
- enhancing the workforce with specialized expertise.
- Capable and flexible framework. reduce waste and venture dismissals, improve efficiency, and cut costs.
- Put together a sensible data foundation for every item.
- Improved communication with the industry regarding scientific matters.
- Ensure consistent information.
- Combine the risk for the board. less testing of the end result.
- Increase the speed of discharge decisions.[9]

SIGNIFICANCE OF QBD :

- High level of assurance regarding the product's quality.
- Cost-effectiveness and efficiency for entrepreneurs and controllers. Reduce potential.
- Increase manufacturing efficiency while lowering expenses and product rejections.
- reviews, expensive penalties, and consistency exercises. Enhance the possibility of open doors for first-cycle endorsement. · Simplify administrative procedures and post-endorsement manufacturing changes.
- Possibility of continuous advancement.

Key aspects of QBD Include:




Fig. 3: Elements of Pharmaceutical Development (ICH Q8R2)

1] The Target Product Quality Profile (TPQP):

TPQP has been defined as a “prospective and dynamic summary of the quality characteristics of a drug product that ideally will be achieved to ensure that the desired quality, and thus the safety and efficacy, of a drug product is realized”. This includes dosage form and route of administration, dosage form strength(s), therapeutic moiety release or delivery and pharmacokinetic characteristics (e.g., dissolution and aerodynamic performance) appropriate to the drug product dosage form being developed and drug product-quality criteria (e.g. sterility and purity) appropriate for the intended marketed product. The concept of TPP in this form and its application is novel in the QBD paradigm⁴. TPP forms the basis for product design in the following way [11]

- ✓ Dosage form
- ✓ Route of administration
- ✓ Strength, maximum and minimum
- ✓ Release/delivery of the drug

- ✓ Pharmacological characteristic
- ✓ Drug product quality criteria
- ✓ Pharmaceutical elegance

2] Essential Quality Aspect

The subsequent action after identifying TPQP is to find the appropriate CQAs. A CQA has been established, as "a physical, chemical, biological, or microbiological property or characteristic that should be within an" the right boundary, range, or distribution to guarantee the intended level of product quality. The process of determining CQAs is known as accomplished via risk analysis in accordance with ICH recommendations Q9. Previous product experience, like that of the the buildup of experience in the laboratory, in non-clinical settings, and in clinical trials with a particular product quality feature is the key in carrying out these risk evaluations. Relevant information from similar situations may also be included in such knowledge. data and molecules taken from literary sources. This data supports the connection between product safety and efficacy and the CQA.

The use of The QBD approach, which is novel to the field, uses robust risk assessment techniques to identify CQAs. The characteristics of oral dosage forms are often those that impact product purity, potency, drug release, and stability. Additional product-specific features, such as, may be included in CQAs for other delivery systems. sterility for parenteral use, adherence properties for inhaled products, and aerodynamic characteristics for inhaled products patches that are transdermal. The CQAs can apply to drug substances, raw materials, and intermediates. also include features that have an impact on the drug product, such as particle size distribution and bulk density. [2,12] CQAs.




Fig.4: Role of (CQA)

3) Important Process Parameter

"Critical process parameters" (CPPs) are defined as "parameters whose variability have an impact on a" Consequently, CQA needs to be monitored or regulated to make sure the process yields the desired results. The ability of a process to produce acceptable quality is known as its "quality" process robustness. while simultaneously maintaining performance and tolerating variations in input. To show the reproducibility and the process capability of a procedure should be examined along with its consistency. The statistical indicator of process capability is the natural variability in a characteristic's process. The most widely used method for process Six sigma is the capability. The value of the tolerances specified for a specific process is known as the process capability index. The method capability, which is defined as follows, distinguishes the characteristic:

Process capability index (CPK) = $\frac{\text{Upper limit of specification} - \text{Lower limit of specification}}{6 \times \text{standard deviation}}$

- Six standard deviations

The procedure is deemed capable if the CPK is significantly above one. When the process capacity is limited, the variability of the process can be gradually reduced using a five-step approach. The following five steps are:

- I. Describe: The desired improvement should be stated explicitly.
- II. Measurement: To determine if the essential product performance characteristics are out, they should be measured. Of specification and employed to the sigma level of the process.
- III. Analyze: Steps should be taken to raise the sigma level when it falls below the goal, beginning with discovering the primary reasons for the excessive fluctuation.
- IV. Enhance: To improve the procedure, process controls should be added and/or the process should be modified. lessen or remove the main sources of variance.
- V. Control: The enhanced production method needs to be monitored and evaluated[13,14]

4] Risk evaluation : A systematic approach to evaluating, controlling, communicating, and reviewing quality risk is quality risk management. about potential threats to the quality of the medicinal product throughout its life cycle. The original list of There may be a large number of possible parameters that can influence CQAs, but they can be narrowed down and ranked by a quality risk assessment (QRA).

QRA is a science based process that can aid identification of CPPs and thus eliminating risk, resulting in high confidence that the analytical method will meet the QTTP under all conditions of use. Thus, a large number of parameters can actually be safely eliminated by use of QRA tools, for example failure mode effects analysis (FMEA) and Ishikawa diagrams on the basis of prior knowledge and initial experimentation. In FMEA the variables are ranked on the basis of the likelihood failure will occur (probability), affect on the pharmaceutical results (severity), and difficulty of detection (detectability), resulting in a risk priority number (RPN). Factors with an RPN above a cut-off level can then be evaluated by subsequent studies whereas factors with a lower RPN can be eliminated from further study^[15]. Ishikawa diagrams segregate risks into different categories, for example those associated with instrumentation, materials, methods, measurements, laboratory climate, and human factors. indicate the Fishbone Diagram for blending unit operation. A fault tree analysis is used to link the potentially critical quality attribute “content uniformity” to a potential failure mode and potential causes, as outlined in Fig.5. Four main causes, i.e., raw and intermediate material properties, processing parameters, equipment and design parameters as well as environmental factors, and the associated sub-causes were identified and afterwards systematically listed in an Ishikawa diagram .





Fig. 5: Risk identification: fault tree analysis of variable content uniformity

5) Design Space:

The ICH Q8(R2) defines the design space as the multidimensional combination and interaction of input variables (e.g., material properties) and process parameters that have been shown to ensure product quality. Working inside the design area is not seen as a transformation. A shift is when you move out of the design area, which usually triggers a regulatory post-approval change procedure. The applicant proposes a design area, which is contingent upon regulatory review and authorization¹. The design space may be dependent on the scale and equipment used; the design space that is identified on the laboratory scale may not apply to the process at the commercial scale. For this reason, unless the design space is proven to be scale-independent, verification at the commercial scale is necessary

Fig.7:Design Space



TOOLS OF QUALITY BY DESIGN:

I] Design of Experiments (DOE):

The structured and organized approach to identifying the connection between the design of experiments (DOE) is called the DOE. elements that have an impact on the outcomes of a process. The idea that DOE may provide returns that are four times higher has been put forth. up to eight times more expensive than performing the experiments in a small amount of time. Use of In QbD, DOE facilitates the collection of the most data possible with the least amount of trials. When Factors in a pharmaceutical process to which DOE is applied are the characteristics of the raw material, such as particle size. Process variables include time and speed, whereas crucial quality characteristics include blend. tablet thickness, uniformity, friability, and hardness. Since every unit operation involves several inputs and outputs It's not possible to experimentally explore all process parameters and variables. DOE The findings may aid in determining the best circumstances, the essential elements that have the greatest impact on CQAs, and the individuals who do not, in addition to specifics like the presence of interactions and synergies between variables, as shown in the illustration. [5] Experimental Design [16,17]

II] Process Analytical Technology (PAT):

"A system for designing, analyzing, and controlling manufacturing through during the processing of essential quality and performance characteristics of raw and in-process measurements processes and materials in order to guarantee the quality of the finished product." The goal of PAT is to "enhance" having a grasp of and control over the production process, which is in line with the high standards of drug quality we have now Quality must be designed into products; it

cannot be tested into them. The plan The key and crucial process variables discovered through process characterization define space. the studies and their acceptable ranges. On-, in-, or at-line PAT pays close attention to these factors. applications. In theory, real-time PAT evaluations might serve as the foundation for ongoing input and lead to a more robust procedure. The NIR functions as a PAT instrument and is helpful in the RTRT (Real Time). Release Testing), which tracks particle size, blend uniformity, granulation, content uniformity, Polymorphism, dissolution, and monitoring the process online, at the line, and offline, thereby minimizing the testing the product's release

III] Risk Management Methodology:

"A systematic process for the assessment, control, and mitigation of quality risks" is how Quality Risk Management is defined. risks to the quality of the medicine product across the product are communicated and assessed life cycle". Risk assessment tools can be used to find and level parameters (such as process, equipment, etc.) that may pose a risk. input materials) that, according to prior knowledge and experience, have the potential to affect product quality. principal empirical findings. While the first list of possible parameters may be quite extensive, it can be changed. as well as given priority in further research (e.g., via a combination of design of experiments, mechanistic models. After the major factors have been determined, they may be examined in more detail (e.g., via a a mix of experimental designs, mathematical models, and investigations that result in mechanistic understanding understanding) in order to gain a deeper comprehension of the process.

By employing well-known risk assessment methods, the pharmaceutical industry and regulators may analyze and manage risks. internal methods and/or management tools, such as:

- Simple methods for facilitating risk management (flowcharts, check lists, etc.);
- Analysis of failure mode effects (FMEA);
- Analysis of Failure Modes, Effects, and Criticality (FMECA).
- Fault Tree Analysis (FTA);
- Critical Control Points and Risk Analysis (HACCP);
- Initial Hazard Analysis (PHA);
- Filtering and ranking risks;[18]

APPLICATION OF QBD :

1.In the tablet Manufacture process :

The pharmaceutical and chemical sectors benefit the most from granulation. The moist granulation Using a fluidized bed dryer and a high shear mixer, the method transforms fine powders into larger molecular sizes. In As a result, we have a consistently sized molecule that has less isolation and is helpful in the future development of stream qualities. exceptional material consistency and enhanced pressure characteristics. It increases the efficiency and quality of production. QBD emphasizes demonstrating how it is feasible to use various methods throughout the tablet manufacturing process. especially plans and circumstances. QBD offers a possible open door to the development of improved models for the batch granulation process. If a Basic The best fundamental quality attribute (CQA) for a finished product has been identified as flowability energy (BFE). then The desired BFE is attained through wet granulation, which will result in high-quality tablets. [19]

2.QBD for RNA platform production:-

RNA-based products represent the most advantageous and sensible advancements for vaccination against infectious diseases. prevention and the development of alternative therapies. The evaluation of cooperation in the item process, logical innovations, and the interaction reveals skills that can address significant system for improvement strengths.

along with the manufacturing process. The RNA innovation will be able to realize its full potential and will be aided by QBD implementation. be crucial for the advancement of pre-capability and regulatory approval of rapid responses in the RNA a plan for the procedure for making something. Direct RNA innovation to safe and efficient RNA antibodies has occurred during the Covid-19 outbreak. change in clinical practice. The rapid progress has been paired with genotyping methods, making this possible. The innovation response is irresistible disease and variation.

❖ Continuous Development Using QbD:

- Determine the needs of the patient
- Recognize CQAs
- Recognize PPs
- Establish the relationship between CPPs and CQAs
- Create and test models
- Create a Design Space
- Design of the Process
- Use Model-Based Process Control Strategy [20]

3) QBD for topical dermatological dosage form:

The most crucial standard being developed for products is the kind of drug measurement system. testing for quality The drug industry uses (QBT) as a method for ensuring the quality and safety of its products. QBD is a A contemporary method of ensuring the security of pharmaceutical goods. In a good dermatological measurement framework (Dosage Form for Topical Dermatology) Different excipients, additives, API, and bundling materials are utilized. Following that in vivo delivery testing should be completed. TDDF multiplexing detailing's robust manufacturing cycle Critical Material Attributes (CMA) and Critical Process Parameters (CPP) are necessary for components. assistance with QBD, not just in the awareness and concern of CMA and CPPS in drug advancement However, it also promotes collaboration between CMA and A quality aspect of the CPP target. The QBD method is therefore strongly recommended for developing TDDF, which will lower the accelerate the course of beneficial products while reducing the cost of progressive phases.

4)QBD approach in the development of hesperetin stacked colloidal nanosponges :

Drug monitoring organizations employ a variety of systems. Colloidal growth is occurring in nanosponges, which has pits and cross-segment-like plans that are extremely likely to deliver the bioactive pharmaceuticals at the target movement's course. which will aid in the distribution of medication in a changed form and in the redesign of its strength. Hesperetin is a kind of flavonoid derived from the hydrolysis of hesperidin, which is present in citrus fruits. regular product HT is used Cyt P450. Urine contains a significant portion of HT Metabolites that are absent from feces. Examples. The transportation of HT is mostly wrapped up by the nanosponges technique, which will aid in increasing solubility, lowering dosage repeat, and enhancing bioavailability. The drug's half-life is extended in the central stream as a result.[21]

CONCLUSION

The QbD approach offers a number of benefits, such as the capacity to Quantify Target Product Profile(QTPP), ongoing improvement, and more. betterment, as well as a greater grasp of goods and procedures. The The quality of medicines is enhanced by the Quality-by-Design (QbD) drug development technique. Regulations have a a major influence on how QbD is implemented. For the pharmaceutical sector, QbD has evolved into a potential scientific tool. industry-specific quality assurance. A QbD results in knowledge spanning the range of product development to business manufacturing. To scientists are able to accurately identify the danger from the start if the quality is improved. There will be a lot more regulation in the future. due to this novel QbD method, there is flexibility. The performance requirements of the approach, not the approach itself, may be the problem. will be registered.

REFERENCES

1. US Food and Drug Administration. Guidance for industry: Q8 Pharmaceutical Development, US Department of Health and Human Service, FDA, Rockville, MD, May 2006.
2. ICH Q8 (R2), Pharmaceutical Development, Part I: Pharmaceutical Development, (2009)
3. A quality by design (QbD) case study on enteric-coated tablets by Kan, S., Lu, J., Liu, J., Wang, J., & Zhao, Y. (2014). pellets: At the laboratory scale, critical factors are screened, and the design space is defined. A journal of Asian studies pharmaceutical sciences, 9,268–278.
4. Sandipan. Int. J Pharm Biomed Res. 2012: 3(2), 100-108
5. Nadpara, N.P. Thumar, R.V. Kalola, V.N. Patel, P.B. Quality By Design (Qbd) : A Complete Review, Int. J. Pharm. Sci. Rev. Res., 17: 20-28(2012)
6. Nadpara, N. P., Thumar, R. V., Kalola, V. N., & Patel, P. B. (2012). QUALITY BY DESIGN (QBD): A COMPLETE REVIEW. International Journal of Pharmaceutical Sciences Review and Research, 17(2), 20-28.
7. Kumar, D., Ancheria , R., Shrivastava, S., Soni, L. S., & Sharma, V. (2019). Review on Pharmaceutical Quality by Design (QbD). Asian Journal of Pharmaceutical Research and Development,7(2), 78-82.
8. Savitha, S., & Devi, K. (2022). Quality by Design(QbD): A Review. Journal of Drug Delivery and Therapeutics,12(2-s), 234-239.
9. 5. Gandhi, A., & Chandrani, R. (2016). Quality by Design (QbD) in Pharmaceutical Industry: Tools, Perspectives and Challenges. Pharma Tutor, 4(11), 12-20.
10. Narke, R. M., & Singh, R. P. (2014). OVERVIEW OF QbD: A CHALLENGE TO THE. Asian Journal of Pharmaceutical Research and Development, 2(4), 42-53.
11. Juran, J.M. Juran on quality by design the new steps for planing quality into goods and services, Revised Edition, free press, newyork, 1992,1-2
12. Purohit, P.J. Shah, K.V. Quality By Design (Qbd): New Parameter for Quality Improvement & Pharmaceutical Drug Development, *Pharma Science Monitor Int J Pharm Sci.*, 4: 1-19 (2013)
13. Purohit, P.J. Shah, K.V. Quality By Design (Qbd): New Parameter for Quality Improvement & Pharmaceutical Drug Development, *Pharma Science Monitor Int J Pharm Sci.*, 4: 1-19 (2013)
14. Glodek, M. Liebowitz, S. McCarthy, R. McNally, G. Oksanen, C. Schultz, T. *et al. Pharm. Eng.*, 26: 1-11 (2006)
15. ICH Q9, Quality Risk Management, (2005)
16. Shah, R.B. Quality by Design in Pharmaceutical Manufacturing, U.S. Food and Drug Administration
17. Bhasin, R. Ghosh, P. Design and development of ondansetron orally disintegrating tablets and its optimization using design of experiment, Int J Pharm Sci Res., 3: 840-847 (2012)
18. Ian House Process Understanding: for Scale-up and Manufacturing method of Active Ingredients, First edition, Wiley-VCH Verlag GmbH & Co. KGaA (2011)
19. Freeman, T., Birkmire, A., Armstrong, & Armstrong, B. (2015). A QbD approach to continuous tablet manufacture. Elsevier, 102, 443-449.
20. Daniel , S., Kis, Z., Kontoravdi, C., & Shah, N. (2022). Quality by Design for enabling RNA platform. Cell Press, xx(xx), 1-16.
21. Rodrigues , K., Nadaf , S., Rarokar, N., Gurav, N., Jagtap, P., Mali, P., et al. (2022). QBD approach for the development of hesperetin-loaded colloidal. Elsevier, 7, 1-12.